Macular Edema - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 66 pages report, published by Global Markets Direct

Keywords : Macular Edema Therapeutic Products under Development, Key Players in Macular Edema Therapeutics, Macular Edema Pipeline Overview, Macular Edema Pipeline, Macular Edema Pipeline Assessment

Report ThumbnailSeptember-2013
Macular Edema - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Edema. Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Macular Edema.
- A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Macular Edema pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Macular Edema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Macular Edema, H2 2013 8
  • Products under Development for Macular Edema - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Discovery and Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 24
  • Assessment by Route of Administration, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Molecule Type, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 28
  • List of Tables
  • Number of Products Under Development for Macular Edema, H2 2013 8
  • Products under Development for Macular Edema - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Products under Investigation by Universities/Institutes, H2 2013 16
  • F. Hoffmann-La Roche Ltd., H2 2013 17
  • Allergan, Inc., H2 2013 18
  • Santen Pharmaceutical Co., Ltd., H2 2013 19
  • Regeneron Pharmaceuticals, Inc., H2 2013 20
  • Promedior, Inc., H2 2013 21
  • Inotek Pharmaceuticals Corporation, H2 2013 22
  • Taiwan Liposome Company, H2 2013 23
  • Assessment by Monotherapy Products, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 28
  • Macular Edema Therapeutics - Drug Profile Updates 45
  • Macular Edema Therapeutics - Discontinued Products 55
  • Macular Edema Therapeutics - Dormant Products 56
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Macular Edema Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Macular Edema 8
  • Macular Edema Therapeutics under Development by Companies 10
  • Macular Edema Therapeutics under Investigation by Universities/Institutes 11
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Discovery and Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Macular Edema Therapeutics - Products under Development by Companies 15
  • Macular Edema Therapeutics - Products under Investigation by Universities/Institutes 16
  • Companies Involved in Macular Edema Therapeutics Development 17
  • F. Hoffmann-La Roche Ltd. 17
  • Allergan, Inc. 18
  • Santen Pharmaceutical Co., Ltd. 19
  • Regeneron Pharmaceuticals, Inc. 20
  • Promedior, Inc. 21
  • Inotek Pharmaceuticals Corporation 22
  • Taiwan Liposome Company 23
  • Macular Edema - Therapeutics Assessment 24
  • Assessment by Monotherapy Products 24
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • ranibizumab - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Eylea - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • PARP Inhibitors - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • INO-6001 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • dexamethasone acetate SR - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • interferon beta-1a - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • AGN-208397 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • trientine hydrochloride - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • PRM-167 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • INO-6002 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • ranibizumab biosimilar - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • Macular Edema Therapeutics - Drug Profile Updates 45
  • Macular Edema Therapeutics - Discontinued Products 55
  • Macular Edema Therapeutics - Dormant Products 56
  • Macular Edema - Product Development Milestones 57
  • Featured News & Press Releases 57
  • Aug 29, 2013: EYLEA Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion 57
  • Jul 26, 2013: EYLEA Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe 57
  • May 21, 2013: Novartis's Ranibizumab Receives NICE Recommendation For Treatment Of Macular Edema 58
  • Apr 11, 2013: NICE Recommends Novartis's Ranibizumab For Treatment Of Macular Edema 59
  • Jan 07, 2013: Bayer Submits VEGF Trap-Eye For Treatment Of Macular Edema Following Central Retinal Vein Occlusion In Japan 59
  • Dec 06, 2012: Bayer Submits EU Marketing Authorization Application For Eylea For Treatment Of Macular Edema Following Central Retinal Vein Occlusion 60
  • Sep 21, 2012: Regeneron Pharma Announces FDA Approval Of Eylea Injection For Macular Edema Following Central Retinal Vein Occlusion 61
  • Sep 05, 2012: New Data For Novartis Drug Lucentis Confirms Long-term Efficacy And Safety Profile And Benefits Of Individualized Treatment 62
  • Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Ozurdex 63
  • Jun 11, 2012: Scottish Medicines Consortium Accepts OZURDEX For Use Within NHS Scotland 64
  • Appendix 65
  • Methodology 65
  • Coverage 65
  • Secondary Research 65
  • Primary Research 65
  • Expert Panel Validation 65
  • Contact Us 66
  • Disclaimer 66

Please select a license type

Share

Related Products

Global Markets DirectMacular Edema - Pipeline Review, H2 2013Product ThumbnailMacular Edema - Pipeline Review, H2 2013, Industry ReportProduct #: 113308
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved